de Zeeuw D - Search Results

1

ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy.

Wapstra FH, Navis GJ, van Goor H, van den Born J, Berden JH, de Jong PE, de Zeeuw D. Wapstra FH, et al. Among authors: de jong pe, de zeeuw d. Exp Nephrol. 2001;9(1):21-7. doi: 10.1159/000020704. Exp Nephrol. 2001. PMID: 11053977

2

Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition.

Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Heeg JE, et al. Among authors: de jong pe, de zeeuw d. Kidney Int. 1991 Oct;40(4):734-41. doi: 10.1038/ki.1991.268. Kidney Int. 1991. PMID: 1660550 Free article. Clinical Trial.

3

Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril.

Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D. Heeg JE, et al. Among authors: de jong pe, de zeeuw d. Am J Nephrol. 1990;10 Suppl 1:94-7. doi: 10.1159/000168201. Am J Nephrol. 1990. PMID: 2175149 Clinical Trial.

4

Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease.

Gansevoort RT, de Zeeuw D, de Jong PE. Gansevoort RT, et al. Among authors: de jong pe, de zeeuw d. Nephrol Dial Transplant. 1995;10(4):497-504. doi: 10.1093/ndt/10.4.497. Nephrol Dial Transplant. 1995. PMID: 7623991 Clinical Trial.

5

Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis.

Wapstra FH, Van Goor H, Navis G, De Jong PE, De Zeeuw D. Wapstra FH, et al. Among authors: de jong pe, de zeeuw d. Clin Sci (Lond). 1996 May;90(5):393-401. doi: 10.1042/cs0900393. Clin Sci (Lond). 1996. PMID: 8665777

6

ACE inhibitors and the kidney. A risk-benefit assessment.

Navis G, Faber HJ, de Zeeuw D, de Jong PE. Navis G, et al. Among authors: de jong pe, de zeeuw d. Drug Saf. 1996 Sep;15(3):200-11. doi: 10.2165/00002018-199615030-00005. Drug Saf. 1996. PMID: 8879974 Review.

7

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease.

Wapstra FH, Navis G, de Jong PE, de Zeeuw D. Wapstra FH, et al. Among authors: de jong pe, de zeeuw d. Exp Nephrol. 1996;4 Suppl 1:47-52. Exp Nephrol. 1996. PMID: 9001897 Review.

8

Proteinuria and progression of renal disease: therapeutic implications.

Gansevoort RT, Navis GJ, Wapstra FH, de Jong PE, de Zeeuw D. Gansevoort RT, et al. Among authors: de jong pe, de zeeuw d. Curr Opin Nephrol Hypertens. 1997 Mar;6(2):133-40. doi: 10.1097/00041552-199703000-00005. Curr Opin Nephrol Hypertens. 1997. PMID: 9146974 Review.

9

ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.

van der Kleij FG, Navis GJ, Gansevoort RT, Heeg JE, Scheffer H, de Zeeuw D, de Jong PE. van der Kleij FG, et al. Among authors: de jong pe, de zeeuw d. Nephrol Dial Transplant. 1997;12 Suppl 2:42-6. Nephrol Dial Transplant. 1997. PMID: 9269699

10

Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?

Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE. Buter H, et al. Among authors: de jong pe, de zeeuw d. Nephrol Dial Transplant. 1997;12 Suppl 2:53-6. Nephrol Dial Transplant. 1997. PMID: 9269701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

659 results

Search Page

Filters